Novo Nordisk A/S (NYSE:NVO) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a strong sell rating to a hold rating in a research note released on Tuesday,Zacks.com reports.

Other equities analysts have also issued reports about the stock. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. BMO Capital Markets reissued a “market perform” rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $64.94.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $46.52 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock’s fifty day moving average is $47.24 and its two-hundred day moving average is $44.61. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The company has a market capitalization of $207.71 billion, a PE ratio of 11.37, a price-to-earnings-growth ratio of 4.30 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The firm had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. As a group, analysts expect that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be issued a $0.5786 dividend. The ex-dividend date is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s payout ratio is currently 42.79%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Capital Investment Counsel LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $3,727,000. Marathon Capital Management lifted its stake in Novo Nordisk A/S by 43.9% in the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock valued at $4,208,000 after buying an additional 25,230 shares in the last quarter. Burkett Asset Management Ltd purchased a new position in Novo Nordisk A/S in the 4th quarter valued at about $1,823,000. Tevis Investment Management boosted its holdings in Novo Nordisk A/S by 65.7% in the 1st quarter. Tevis Investment Management now owns 74,090 shares of the company’s stock worth $2,813,000 after buying an additional 29,390 shares during the last quarter. Finally, XXEC Inc. boosted its holdings in Novo Nordisk A/S by 487.1% in the 1st quarter. XXEC Inc. now owns 545,020 shares of the company’s stock worth $20,029,000 after buying an additional 452,185 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market is unlikely to be “winner-take-all,” arguing that patients will seek differentiated treatments, including pills. This supports Novo’s ability to compete beyond its current injectable products. Reuters article
• Positive Sentiment: Oral Wegovy prescriptions reportedly reached a record, while management sees a long runway for GLP-1 adoption as obesity remains widespread and treatment could eventually reduce healthcare costs. Fox Business article
• Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, adding a commercial opportunity in diabetes care beyond the obesity franchise. Awiqli availability article
• Neutral Sentiment: Erste Group raised its FY2026 EPS estimate to $3.27 from $3.20, although that remains below the broader consensus estimate of $3.39. Erste Group estimate article
• Negative Sentiment: Berenberg downgraded NVO from “buy” to “hold,” saying much of the anticipated Wegovy-pill upside is already reflected in the valuation and that the stock’s multiple may revert toward the European pharmaceutical average. Berenberg downgrade article
• Negative Sentiment: Management acknowledged that Eli Lilly is gaining market share. Investors remain concerned about flat Wegovy sales, pricing pressure, pipeline setbacks and Lilly’s competitive position in oral obesity treatments. BeInCrypto article
• Negative Sentiment: Novo is defending a lawsuit against Lilly over weight-loss-drug advertising. Although the company says competition must be fair, the litigation adds uncertainty and could distract from the commercial battle. CNBC article

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.